These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 25627551)

  • 1. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab.
    Goldblatt EM; Erickson PA; Gentry ER; Gryaznov SM; Herbert BS
    Breast Cancer Res Treat; 2009 Nov; 118(1):21-32. PubMed ID: 18853252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
    Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
    Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
    Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
    Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
    Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
    Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.
    Brennan SK; Wang Q; Tressler R; Harley C; Go N; Bassett E; Huff CA; Jones RJ; Matsui W
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
    Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
    Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
    J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
    Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.